Strategic Capital Alternatives’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Strategic Capital Alternatives’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	$51K	Buy	819 +99	+14%	+$7.8K	0.01%	215
2015 Q2	$55K	Hold	720	–	–	0.01%	288
2015 Q1	$54K	Buy	+720	New	+$50.3K	0.01%	236

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Strategic Capital Alternatives's XBI Position: Q3 2015 in Review

Strategic Capital Alternatives increased its State Street SPDR S&P Biotech ETF (XBI) stake by 14% in Q3 2015, buying an estimated $7.8K and bringing the position to 819 shares worth $51K. The position accounts for 0.01% of the portfolio, ranked #215.

Strategic Capital Alternatives first reported a position in XBI in Q1 2015 and has held it in 3 quarters since. The position peaked at $55K in Q2 2015. 196 funds tracked by Wall St. Rank hold XBI as of Q3 2015.

Strategic Capital Alternatives held 819 shares of State Street SPDR S&P Biotech ETF worth $51K as of Q3 2015.
Strategic Capital Alternatives bought 99 State Street SPDR S&P Biotech ETF shares in Q3 2015, an estimated $7.8K.
State Street SPDR S&P Biotech ETF made up 0.01% of Strategic Capital Alternatives's portfolio in Q3 2015, its #215 holding.
Strategic Capital Alternatives first reported a position in State Street SPDR S&P Biotech ETF in Q1 2015 and has held it in 3 quarters since.
Strategic Capital Alternatives's State Street SPDR S&P Biotech ETF position peaked at $55K in Q2 2015.
196 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2015.

Based on Strategic Capital Alternatives's 13F filing for Q3 2015, filed 16 Nov 2015.